コンテンツへスキップ
Merck

B-034

Bupropion hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C13H19Cl2NO
CAS番号:
分子量:
276.20
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

Bupropion hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

InChI key

HEYVINCGKDONRU-UHFFFAOYSA-N

InChI

1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

SMILES string

Cl.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

grade

certified reference material

description

Drug Control: Kábítószer / Narcotic Drug (Hungary), 78/2022. (XII. 28.) BM rendelet

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Kábítószer / Narcotic Drug (Hungary), 78/2022. (XII. 28.) BM rendelet

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

General description

A certified solution standard suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing and pharmaceutical research. Bupropion is an antidepressant and smoking cessation drug sold under the trade names Wellbutrin® and Zyban®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Wellbutrin is a registered trademark of GlaxoSmithKline LLC
Zyban is a registered trademark of Everris International B.V.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

保管分類

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Kamran Siddiqi et al.
Annals of internal medicine, 158(9), 667-675 (2013-05-08)
Tobacco use is responsible for a large proportion of the total disease burden from tuberculosis. Pakistan is one of the 10 high-burden countries for both tuberculosis and tobacco use. To assess the effectiveness of a behavioral support intervention and bupropion
Daniel T Tsoi et al.
The Cochrane database of systematic reviews, 2(2), CD007253-CD007253 (2013-03-02)
Individuals with schizophrenia smoke more heavily than the general population and this contributes to their higher morbidity and mortality from smoking-related illnesses. It remains unclear what interventions can help them to quit or to reduce smoking. To evaluate the benefits
Philip Tønnesen
European respiratory review : an official journal of the European Respiratory Society, 22(127), 37-43 (2013-03-05)
The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replacement therapy (NRT) or bupropion SR. Varenicline and combination of two NRTs is equally effective, while varenicline alone is more effective than either NRT or bupropion SR. NRT
Leonie S Brose et al.
Mayo Clinic proceedings, 88(3), 226-233 (2013-03-16)
To compare the effectiveness of varenicline and combination nicotine replacement therapy (NRT) for treating smokers attempting to stop, as it is unclear which of the 2 is more effective. Data from 167,487 treatment episodes in patients from 42 National Health
Frank T Leone et al.
Chest, 143(5 Suppl), e61S-e77S (2013-05-10)
Continued tobacco use in the setting of lung cancer management is frequently confounding and always of critical importance. We summarized the published literature concerning the management of tobacco dependence in patients with lung cancer and offer recommendations for integrating dependence

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)